Thromboxane A(2) generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction

• Published in: Circulation journal : official journal of the Japanese Circulation Society 2013, Vol.77 (11), p.2786-2792
• Main Authors: DeFilippis, Andrew P, Oloyede, Oluwasegun S, Andrikopoulou, Efstathia, Saenger, Amy K, Palachuvattil, Joel M, Fasoro, Yetunde A, Guallar, Eliseo, Blumenthal, Roger S, Kickler, Thomas S, Jaffe, Allan S, Gerstenblith, Gary, Schulman, Steven P, Rade, Jeffrey J
• Format: Article
• Language: English
• Subjects: Aged; Aspirin - administration & dosage; Blood Platelets - enzymology; Coronary Artery Disease - blood; Coronary Artery Disease - drug therapy; Coronary Artery Disease - urine; Creatinine - blood; Creatinine - urine; Cyclooxygenase 1 - metabolism; Cyclooxygenase Inhibitors - administration & dosage; Female; Humans; Male; Middle Aged; Myocardial Infarction - blood; Myocardial Infarction - drug therapy; Myocardial Infarction - urine; Platelet Aggregation - drug effects; Thrombosis - blood; Thrombosis - drug therapy; Thrombosis - urine; Thromboxane A2 - blood; Thromboxane A2 - urine; Thromboxane B2 - analogs & derivatives; Thromboxane B2 - blood; Thromboxane B2 - urine
• ISSN: 1347-4820
• DOI: 10.1253/circj.CJ-12-1421

Aspirin's therapeutic action is via inhibition of platelet cyclooxygenase 1 (COX-1) thromboxane A2 (TxA2) production. The aim of this study was to evaluate TxA2 production, in the absence of platelet COX-1 activity, in coronary atherosclerotic heart disease patients with and without atherothrombotic myocardial infarction (MI). TxA2 production, in the absence of platelet COX-1 activity, was evaluated in 44 patients taking aspirin on 3 commercially available assays that detect metabolites of TxA2 in the urine. Two assays measure urine 11-dehydro-thromboxane B2 (TxB2) alone and 1 measures urine 11-dehydro-TxB2 plus 11-dehydro-2,3-dinor-TxB2. Platelet COX-1 inhibition was confirmed on